Coherus BioSciences (CHRS) Tops Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.02 +2.00%
Revenue Growth %: +37.8%
Financial Fact:
Total operating expenses: 234.36M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Revenue Growth %: +37.8%
Financial Fact:
Total operating expenses: 234.36M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.27), $0.11 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $74.6 million versus the consensus estimate of $81.78 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Rollins falls 7% on third quarter earnings and revenue miss
- Graco falls 7% as third quarter results miss estimates
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
